Showing results (41-50 of 151) with videos related to

Sort By:
Pageof 16
Neurophysiologie Clinique = Clinical Neurophysiology|December 3, 2014
Kinematic and kinetic analysis of the inter- and intra-applicator assessment of the Babinski reflexC Dafkin, A Green, S Kerr, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1994
Diagnostics of malignant lymphomas with ultrasound guided 1.2 mm biopsy-gunM Kälkner, S Rehn, T Andersson, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|March 5, 2008
Intraplacental choriocarcinoma arising in a second trimester placenta with partial hydatidiform moleFabiola Medeiros, Michael J Callahan, Julia A Elvin, et al.
Case Reports in Oncology|July 20, 2018
Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung CancerEva J Gordon, David Parker, Kelly Barth, et al.
The Oncologist|February 2, 2018
Tumor Mutational Burden Guides Therapy in a Treatment Refractory <i>POLE-</i>Mutant Uterine CarcinosarcomaMunveer S Bhangoo, Peter Boasberg, Pareen Mehta, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 20, 2020
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovaryDouglas I Lin, Jonathan K Killian, Jeffrey M Venstrom, et al.
Biology of Reproduction|February 24, 2006
Regulation of growth differentiation factor 9 expression in oocytes in vivo: a key role of the E-boxChangning Yan, Julia A Elvin, Yi-Nan Lin, et al.
Molecular Endocrinology (Baltimore, Md.)|June 1, 2002
Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertilitySimona Varani, Julia A Elvin, Changning Yan, et al.
Gynecologic Oncology Reports|June 17, 2024
Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with <i>ESR1</i> gene amplificationJenny L Soiffer, Alexander J Fife, Shrikanth S Gadad, et al.
European Urology|January 1, 1993
Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomyM Häggman, M Hellström, G Aus, et al.
Pageof 16